Fig. 1From: Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acidSurvival from start of treatment, a for the entire cohort, b responders vs. nonresponders, landmark analysis at 1 year (at 2 years, 44% of responders are alive compared to 0% of non-responders) c) according to VPA serum level </≥70 μg/mlBack to article page